262 related articles for article (PubMed ID: 25129599)
1. Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease.
Bousamra M; Schumer E; Li M; Knipp RJ; Nantz MH; van Berkel V; Fu XA
J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1074-80; discussion 1080-1. PubMed ID: 25129599
[TBL] [Abstract][Full Text] [Related]
2. Breath carbonyl compounds as biomarkers of lung cancer.
Li M; Yang D; Brock G; Knipp RJ; Bousamra M; Nantz MH; Fu XA
Lung Cancer; 2015 Oct; 90(1):92-7. PubMed ID: 26233567
[TBL] [Abstract][Full Text] [Related]
3. High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds.
Schumer EM; Trivedi JR; van Berkel V; Black MC; Li M; Fu XA; Bousamra M
J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1517-22; discussion 1522-4. PubMed ID: 26412316
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of lung cancer using exhaled breath.
Fu XA; Li M; Knipp RJ; Nantz MH; Bousamra M
Cancer Med; 2014 Feb; 3(1):174-81. PubMed ID: 24402867
[TBL] [Abstract][Full Text] [Related]
5. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
6. Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection.
Schumer EM; Black MC; Bousamra M; Trivedi JR; Li M; Fu XA; van Berkel V
Ann Thorac Surg; 2016 Oct; 102(4):1095-100. PubMed ID: 27293148
[TBL] [Abstract][Full Text] [Related]
7. Exhaled biomarkers in lung cancer.
Horváth I; Lázár Z; Gyulai N; Kollai M; Losonczy G
Eur Respir J; 2009 Jul; 34(1):261-75. PubMed ID: 19567608
[TBL] [Abstract][Full Text] [Related]
8. Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma.
Kumar S; Huang J; Abbassi-Ghadi N; Mackenzie HA; Veselkov KA; Hoare JM; Lovat LB; Španěl P; Smith D; Hanna GB
Ann Surg; 2015 Dec; 262(6):981-90. PubMed ID: 25575255
[TBL] [Abstract][Full Text] [Related]
9. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
10. Correlation between matrix metalloproteinase 9 and 18F-2-fluoro-2-deoxyglucose-positron emission tomography as diagnostic markers of lung cancer.
Fiorelli A; Rizzo A; Messina G; Izzo A; Vicidomini G; Pannone G; Santini M; Di Domenico M
Eur J Cardiothorac Surg; 2012 Apr; 41(4):852-60. PubMed ID: 22219420
[TBL] [Abstract][Full Text] [Related]
11. Volatile signature for the early diagnosis of lung cancer.
Gasparri R; Santonico M; Valentini C; Sedda G; Borri A; Petrella F; Maisonneuve P; Pennazza G; D'Amico A; Di Natale C; Paolesse R; Spaggiari L
J Breath Res; 2016 Feb; 10(1):016007. PubMed ID: 26857451
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development of volatile exhaled breath signatures of lung cancer.
Mazzone PJ; Wang XF; Lim S; Jett J; Choi H; Zhang Q; Beukemann M; Seeley M; Martino R; Rhodes P
Ann Am Thorac Soc; 2015 May; 12(5):752-7. PubMed ID: 25965541
[TBL] [Abstract][Full Text] [Related]
13. Detection of precancerous gastric lesions and gastric cancer through exhaled breath.
Amal H; Leja M; Funka K; Skapars R; Sivins A; Ancans G; Liepniece-Karele I; Kikuste I; Lasina I; Haick H
Gut; 2016 Mar; 65(3):400-7. PubMed ID: 25869737
[TBL] [Abstract][Full Text] [Related]
14. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD.
Dragonieri S; Annema JT; Schot R; van der Schee MP; Spanevello A; Carratú P; Resta O; Rabe KF; Sterk PJ
Lung Cancer; 2009 May; 64(2):166-70. PubMed ID: 18834643
[TBL] [Abstract][Full Text] [Related]
15. Breath testing as a method for detecting lung cancer.
Taivans I; Bukovskis M; Strazda G; Jurka N
Expert Rev Anticancer Ther; 2014 Feb; 14(2):121-3. PubMed ID: 24467216
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer biomarkers in exhaled breath.
Amann A; Corradi M; Mazzone P; Mutti A
Expert Rev Mol Diagn; 2011 Mar; 11(2):207-17. PubMed ID: 21405971
[TBL] [Abstract][Full Text] [Related]
17. Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.
Nardi-Agmon I; Abud-Hawa M; Liran O; Gai-Mor N; Ilouze M; Onn A; Bar J; Shlomi D; Haick H; Peled N
J Thorac Oncol; 2016 Jun; 11(6):827-37. PubMed ID: 26968885
[TBL] [Abstract][Full Text] [Related]
18. Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease.
Zou Y; Zhang X; Chen X; Hu Y; Ying K; Wang P
Cancer Biomark; 2014; 14(5):371-9. PubMed ID: 25171479
[TBL] [Abstract][Full Text] [Related]
19. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry.
Ligor M; Ligor T; Bajtarevic A; Ager C; Pienz M; Klieber M; Denz H; Fiegl M; Hilbe W; Weiss W; Lukas P; Jamnig H; Hackl M; Buszewski B; Miekisch W; Schubert J; Amann A
Clin Chem Lab Med; 2009; 47(5):550-60. PubMed ID: 19397483
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive detection of lung cancer by analysis of exhaled breath.
Bajtarevic A; Ager C; Pienz M; Klieber M; Schwarz K; Ligor M; Ligor T; Filipiak W; Denz H; Fiegl M; Hilbe W; Weiss W; Lukas P; Jamnig H; Hackl M; Haidenberger A; Buszewski B; Miekisch W; Schubert J; Amann A
BMC Cancer; 2009 Sep; 9():348. PubMed ID: 19788722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
